SCHEMBL1505008

SCHEMBL1505008

CCCCCCCCCS(=O)(=O)c1nc2ccccc2s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.58
SMN1; SMN2 Q16637 6/20 0.58
MAPT P10636 5/20 0.58
LMNA P02545 4/20 0.58
HTT P42858 4/20 0.58
KMT2A Q03164 4/20 0.58
L3MBTL1 Q9Y468 2/20 0.56
MEN1 O00255 1/20 0.56
PSMB8 P28062 1/20 0.54
PSMB5 P28074 1/20 0.54
CA2 P00918 5/20 0.53
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA4 P22748 1/20 0.53
CA7 P43166 1/20 0.53
CA14 Q9ULX7 1/20 0.53
TP53 P04637 1/20 0.51
HSD17B10 Q99714 1/20 0.46
KDM4E B2RXH2 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10807598 0.99 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL3595617 0.83 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL30149949 0.83 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL13164434 0.82 SMN1; SMN2 (0.56) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL20566310 0.81 SMN1; SMN2 (0.57) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL27839385 0.80 PSMB8 (0.50) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL9393802 0.79 PSMB8 (0.65) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL9439692 0.79 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL6803565 0.79 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL31635992 0.78 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2MAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2292610-A1 Macrolides with VEGF transcription suppression activity MERCIAN CORPORATION (JP) 2011-03-09 EP disclosed
US-7667052-B2 Bioactive substance EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-02-23 US disclosed
US-20060079572-A1 Novel bioactive substance MICROBIOPHARM JAPAN CO., LTD. (JP) 2006-04-13 US disclosed
US-7026352-B1 Physiologically active substances MERCIAN CORPORATION (JP) 2006-04-11 US disclosed
EP-1380579-A1 NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES MERCIAN CORPORATION (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079572-A1 Novel bioactive substance CASP7, MMP7, BMP4 ALDH1A1 3321/4885SMN1; SMN2 3603/4885MAPT 3433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.